A fully executed license is required for use of the MINI Kid International Neuropsychiatric Interview (MINI) in any language. To license the MINI directly from Dr. Sheehan, the author and copyright holder, you will need complete his license agreement.  CLICK HERE to download a template license agreement for use.   Note that a license is needed for use of the MINI 5.0, MINI 6.0 and MINI 7.0.2.

Dr. Sheehan only provides consultation, guidance on regulatory agency questions, and training to those who license the MINI / MINI Kid or scales directly from him. Contact Dr. Sheehan at davidVsheehan@gmail.com for additional information. If you do not see a QR code on the MINI Kid you are using linking back to this website then you did not get the MINI Kid from the author and Copyright Holder.  Dr. David V. Sheehan is the Copyright Holder, Trademark Holder, and author of the MINI Kid for DSM-5 in all languages.  This copyright for the MINI has been registered with the US Copyright Office.

The cost of licensing the standard MINI or the MINI Kid is $15 USD for each use, i.e. each administration to a subject and/or each use in training. The cost of licensing other versions of the MINI or MINI Kid (e.g., the more extended Psychotic Disorders version, the version for Suicidality Disorders or for ADHD Disorders) is the same. An additional custom disorder module costs an additional $4 per administration per module in addition to the standard $15 for the standard MINI.

Note: Non-profit institutions sometimes incorrectly assume that the license fee does not apply because they are “not-for-profit”. The licensing fee applies to all uses.

How to calculate the total number of uses. Typically, the MINI is used to screen potential subjects for eligibility for a study. The total number of MINI uses will depend on the study’s eligibility (inclusion and exclusion) criteria, the available population, and the likelihood of subjects dropping out before the baseline visit is completed.

As a rule of thumb, you will need to screen 200-400 or more subjects to get a yield of 100 subjects. Our recommendation is that you take a minimum 2:1 ratio to calculate the number of uses for most conditions and a higher ratio for studies where you expect more subjects will be excluded or drop out before they are randomized.

Pricing Example:

• 1 administration of the MINI to 100 subjects during the entire study = 100*$15
• 2 administrations of the MINI to 100 subjects during the entire study = 100*2*$15
• If the MINI is used as a screening tool to get a yield of 100 into the study, then you are likely to need to use the MINI at least 200 times (2:1 ratio) or 200*$15. If you plan to administer the MINI one more time during the study to the remaining 100, that is an additional 100*$15. For more information on the recommended 2:1 ratio please download the License agreement – click here.
• Please also always account for any additional use for training uses of the MINI

The license and license fee applies to all uses.

Dr. Sheehan licenses the MINI Kid International Neuropsychiatric Interview in paper format for distribution as follows: (1) in paper form for any uses, or (2) in fixed-pdf form, paper form, or both for use in clinical or academic research trials or studies.

You can use the MINI

• To provide a shorter alternative to longer diagnostic interviews to systematically assess children and adolescents for DSM-5 diagnoses for research, for clinical practice, or for detailed forensic examination.
• To select subjects for a clinical trial. For example, the MINI-Kid can be used in a study of the effectiveness of a new treatment for child ADHD to ensure that all the study subjects meet DSM-5 criteria for ADHD) and that none meet criteria for a current Psychotic or Substance Use Disorder).
• To assess the incidence or prevalence of psychiatric disorders and suicidality in a population. The MINI-Kid has been used for this purpose in epidemiology studies in countries such as Canada, China, Spain, the GCC (Gulf Cooperation Countries, including Egypt, Bahrain, Oman, Qatar, Saudi Arabia and the UAE), Saudi Arabia, South India, Uganda and in Syrian refugee children in Lebanon. It has also been used to assess the prevalence of mental health disorders in special populations such as children and adolescents with physical conditions.
• To explore relationships between variables such as religious attitudes and OCD symptoms in adolescents, adolescent screen time and depressive episodes, to name just two such studies.

The MINI-Kid is unique in being much shorter than comparable diagnostic interviews for children such as the K-SADs while still covering the major diagnostic categories seen in children and adolescents in mental health settings and the general population (Sheehan et al., 2010). It also differs from comparable interviews and in focusing more on the presence of current as opposed to past disorders and conditions and in its inclusion of a Suicidality module.

The MINI-KID is a clinician rated structured clinical interview designed to be administered by mental health professionals or researchers who have been clinically trained in its use. There is no minimum degree requirement. Our recommendation is that the rater be a licensed clinician in mental health with adequate diagnostic assessment experience. However, we leave the final decision of selection and credentialing of raters up to the local sites. To view our training platform CLICK HERE.

Dr. Sheehan only provides consultation, guidance on regulatory agency questions, and training to those who license the MINI / MINI Kid or scales directly from him. Contact Dr. Sheehan at davidVsheehan@gmail.com for additional information. If you do not see a QR code on the MINI Kid you are using linking back to this website then you did not get the MINI Kid from the author and Copyright Holder.  Dr. David V. Sheehan is the Copyright Holder, Trademark Holder, and author of the MINI Kid for DSM-5 in all languages.  This copyright for the MINI has been registered with the US Copyright Office.

Yes. Dr. Sheehan’s license allows you to administer the MINI-Kid remotely as long as you complete the interview on paper as a primary source document. It is up to your protocol to determine how appropriate remote administration is for your patient population. Whether the interview is with the child and parent together, an older adolescent, or only the parent (Kid-Parent version), Dr. Sheehan’s recommendation is to conduct the interview using video, such as Zoom or Skype, rather than phone. The MINI Kid is a clinician rated structured clinical interview and many questions on the MINI-Kid require clinical observation of the child/adolescent. Be sure to review HIPAA and GDPR privacy rules. If you are doing research, you should also review other applicable rules to make sure that remote administration is acceptable to any agency, such as the FDA, who may have oversight of your research.

The MINI Kid is a clinician rated structured clinical interview also known as a clinical decision support tool designed to assess, document, and confirm the presence of major DSM-5 psychiatric disorders and suicidality in children and adolescents aged 6-17 years.  The MINI and MINI Kid are both frequently identified as a clinical decision support tool and as a Clinician-reported Outcome measure (Clin-RO), a subcategory of Clinical Outcome Assessment measures (COA).

No. The MINI-Kid is an interview. It is not valid if it is only patient-rated. The reason is that some modules, notably the psychotic disorders module and the module to rule out medical, organic, drug causes, require clinicians to observe the patient, elicit examples, and use clinical judgement. It is not possible to document, confirm, or rule out many of the diagnoses including, for example, a psychotic disorder, a major depressive disorder (MDD), or a bipolar disorder, without clinician input. Clinician input and judgment are also required to determine the primary diagnosis on the summary page.

The MINI Kid used in paper format as a primary source document has been cited in over 1,500 publications.

We recommend using the following citations (in order of priority) in referencing the MINI-Kid:

1. Sheehan DV, Sheehan KH, Shytle RD, Janavs J, Bannon Y, Rogers JE, Milo KM, Stock SL, Wilkinson B. Reliability and Validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI–KID). J Clin Psychiatry; 2010;71(3):313-326. DOI:http://dx.doi.org/10.4088/JCP.09m05305whi
2. Duncan L, Georgiades K, Wang, Van Lieshout, RJ et al. Psychometric Evaluation of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid).Psychological Assessment,2018; 30(7), 916–928. https://doi.org/10.1037/pas0000541
3. Högberg, C., Billstedt, E., Björck, C. et al. Diagnostic validity of the MINI-KID disorder classifications in specialized child and adolescent psychiatric outpatient clinics in Sweden.BMC Psychiatry, 2019 19( 142), 2121-8. https://doi.org/10.1186/s12888-019-2121-8.

The primary reference for the MINI-Kid is found within the License Agreement from Dr. Sheehan and the MINI-Kid itself. For any scientific questions relating to the MINI-Kid, contact David V Sheehan MD MBA directly by email at: davidVsheehan@gmail.com

The MINI Kid Screen is a much shorter 2-page screening tool. It can be patient rated or clinician administered. The MINI Kid Screen contains only the first 2-4 screening questions from the standard MINI Kid’s modules. The MINI Kid Screen cannot assess, document or confirm a DSM-5 or ICD-10 diagnoses. It is typically used for screening in primary care.

The MINI Kid Tracking is a collection of symptom severity scales derived from the standard MINI Kid. It has the same modules as the MINI Kid but converts the MINI Kid’s binary (Yes/No) responses for key symptoms into dimensional response options (0-4), (none / mild / moderate / very / extreme. It can be patient rated or clinician administered.

The MINI Kid Tracking is not a structured diagnostic interview. It cannot assess, document, or confirm DSM-5 or ICD-10 diagnoses It is typically used to track  and monitor change in a symptom cluster and treatment response over time after an initial diagnostic interview using the MINI Kid is conducted. A benefit is that each of the tracking modules yields a score that can be plotted quantitatively on a graph.

It may be sufficient to only track symptoms for the primary diagnosis (e.g., by using the MDE Module for a patient with a primary diagnosis of MDD). However, if the patient has complicating comorbid conditions such as suicidality or substance use, or you know that a treatment could produce new unintended treatment emergent symptoms (e.g., mania), it may be prudent to administer additional tracking modules.

Yes. Please CLICK HERE for a watermarked preview copy for review only or contact Dr. Sheehan at davidVsheehan@gmail.com.

Yes, Dr. Sheehan can design a customized version of the MINI Kid with customized additional modules to meet the needs of a specific study or clinical setting. Contact Dr. Sheehan at davidVsheehan@gmail.com to discuss a customized version.

Requests to access existing non-English translations or for any new translations should be submitted through MAPI Research Trust’s ePROVIDE COA platform at

https://eprovide.mapi-trust.org/ using the following process:

1. Go to Submit a request
2. If you haven't registered yet, you'll be asked to sign up for free
3. Complete the request form. Please attach a copy of the signed and fully executed license agreement signed by Dr. David V Sheehan.

We provide training through our training platform.  Please review our Training page and learn how you or your raters can be trained by the author/copyright holder of the MINI/MINI Kid.  Certificate of Completion signed by Dr. David V Sheehan is included for any rater who completes the training and can be submitted to regulatory bodies along with your own certification process.

Dr. Sheehan only provides consultation, guidance on regulatory agency questions, and training to those who license the MINI / MINI Kid or scales directly from him. Contact Dr. Sheehan at davidVsheehan@gmail.com for additional information.

NOTE: If you do not see a QR code on the MINI Kid you are using linking back to this website then you did not get the MINI Kid from the author and Copyright Holder.  Dr. David V. Sheehan is the Copyright Holder, Trademark Holder, and author of the MINI Kid for DSM-5 in all languages.  This copyright for the MINI has been registered with the US Copyright Office.

The cost for training is currently $100 USD per trainee per training for each timepoint of training.  There are additional setup fees if any of the following apply:

• for large groups of 20 or more coupon code uses
• if training is being used in a clinical research study or as part of a drug development program
• if data from the study are being submitted to a regulatory agency
• if training must be duplicated for any reason (e.g., for each recertification time point or for non-English-language training).

To calculate training costs please download our Training Form or contact Jennifer M. Giddens at training@harmresearch.org

We can provide subtitles or voice over for the training video(s) in different languages.  We can also have the quiz(es) and the guide(s) for enrolling in training translated.  If you want the quiz in any languages other than English, we will need to set-up a copy of the training in this specific language.  The set-up fee will apply for each language that you want the training set-up in. For more information please contact Jennifer M. Giddens at training@harmresearch.org

Dr. Sheehan only provides consultation, guidance on regulatory agency questions, and training to those who license the MINI / MINI Kid or scales directly from him. Contact Dr. Sheehan at davidVsheehan@gmail.com for additional information.

We provide a Training Guide to the individual who purchases the training and it is up to them to them provide this guide to the trainee.  This guide is very important to ensure coupon codes are used properly and training is not compromised.

Because of GDPR and other privacy laws, we require trainees to enroll themself in the training using a coupon code.  We allow each trainee to have access to the training for up to 30 days.  (For example, if a trainee enrolled in the training on October 25th, 2022, their training access  expired on November 25th, 2022.  If another trainee enrolled on October 28th, 2022 that trainee’s access expired on November 28th, 2022.)  By allowing a trainee to enroll in the training and complete the training on their own time they usually immediately complete the training when they access the training.  We will send a guide that walks trainees through the entire process of enrolling in and completing the training.  You should provide this guide to the trainees.

We will restrict the coupon code to only work for the specific training course(s) of your choice.  The one downside is that we cannot oversee that those using the coupon code are people you want to have trained.  If someone shared the code with a friend, that training would count against the total number of trainings you purchased.

We recommend providing training for a trainee shortly before their site will begin recruitment or direct use of the scale / structured interview.  We do not recommend training users of the scales / structured interviews too far in advance of them using the scales / structured interview, unless they are already experienced users of the scale / structured interview.

The training materials were personally created by the author and copyright holder of the scale or structured interview.  The training courses include a video presentation and a quiz.  After both of these are completed in full, a certificate of completion of training is generated.  User certification is left up to the local site or sponsor and is usually a credentialing issue. 

Please visit our Training page or review our Training Form for more details.

A fully executed license is required for use of the Sheehan Disability Scale (SDS) in any language. To license the SDS directly from Dr. Sheehan, the author and copyright holder, you will need complete his license agreement. Click here to learn more about the SDS or to download a License for use.

Dr. Sheehan only provides consultation, guidance on regulatory agency questions, and training to those who license the SDS directly from him. Contact Dr. Sheehan at davidVsheehan@gmail.com for additional information. If you do not see a QR code on the SDS you are using linking back to this website then you did not get the SDS from the author and Copyright Holder.  Dr. David V. Sheehan is the Copyright Holder, Trademark Holder, and author of the SDS in all languages.  This copyright for the SDS has been registered with the US Copyright Office.

The cost of licensing the SDS is $4 USD for each use, i.e. each administration to a subject and/or each use in training.

Note: Non-profit institutions sometimes incorrectly assume that the license fee does not apply because they are “not-for-profit”. The licensing fee applies to all uses.

The license and license fee applies to all uses.

Dr. Sheehan licenses the SDS in paper format for distribution as follows: (1) in paper form for any uses, or (2) in fixed-pdf form, paper form, or both for use in clinical or academic research trials or studies.

Many patients suffer impairment of functioning at work, at school, in social settings or at home above and beyond their symptoms.  Insurance companies, employers, government agencies, clinicians and drug companies seeking regulatory approval want to be assured that treatment not only improves symptoms but also restores functioning. The SDS can be used:

• To assess and monitor the severity of functional impairment over time and in response to treatment in primary care as well as mental health settings.
• To identify and track disability and functional impairment as an efficacy outcome measure, adverse event and/or treatment emergent effect in clinical trials and treatment outcome studies.
• To provide documentation of disability and impairment in detailed forensic evaluations.
• To detect and describe the incidence or prevalence and severity of disability and impairment in population research including national and international epidemiology studies and community surveys.

The SDS is unique in using a discretized analog (Discan) metric that subjects with different cognitive orientations (verbal, numeric, and visual spatial) can easily follow. Some people rate numerically (”he was 6’3” tall”), others use verbal descriptors (“he was very tall”), and still others communicate by rating space visually (using their hands to point while commenting “he was this tall”). Some choose a combination of two or all three methods. For each of its functional domains (work / social / family life), the SDS allows subjects to simultaneously anchor their perceptions of their own impairment all three ways (verbally, numerically and visually-spatially). It also allows enough points of discrimination so that subjects can make fine distinctions in degrees of impairment. This format makes the SDS uniquely sensitive to efficacy signals in treatment studies. Additionally, the SDS contains two numeric measures for “days lost” and “days underproductive” that can be used to assess the impact of disability on work and productivity.

No minimum qualification is needed to administer the SDS. However, in research settings where precision is required, training in the use of the SDS is recommended. For more information about training, CLICK HERE.

Note:Dr. Sheehan only provides consultation, guidance on regulatory agency questions, and training to those who license the Sheehan Disability Scale (SDS directly from him. Contact Dr. Sheehan at davidVsheehan@gmail.com for additional information.  If you do not see a QR code on the Sheehan Disability Scale (SDS) you are using linking back to this website, then you did not get the Sheehan Disability Scale (SDS) from the author and Copyright Holder.  Dr. David V. Sheehan is the Copyright Holder, Trademark Holder and author of the Sheehan Disability Scale (SDS) in all languages.  This copyright for the SDS has been registered with the US Copyright Office.

Yes. Dr. Sheehan’s license allows you to administer the SDS remotely as long as you complete the interview on paper as a primary source document. It is up to your protocol to determine how appropriate remote administration is for your patient population. For best results, Dr. Sheehan’s recommendation is to conduct the interview using video, such as Zoom or Skype, rather than phone. The SDS can be rated by patient or clinician. Because of this flexibility it is useful for inpatients as well as outpatients and can also be used in community and population studies.

If you are doing research, you should also review other applicable rules to make sure that remote administration is acceptable to any agency, such as the FDA, who may have oversight of your research.

The standard version of the SDS for adults meets most needs, most of the time in clinical and research settings. The pediatric version (SDS-P) is useful for children since it can be parent or clinician rated for children over the age of 6-11. We recommend the adolescent version (SDS-A) for adolescents age 12-17 since it can be either self-rated or clinician rated.

Yes. Please CLICK HERE for a watermarked preview copy for review only or contact Dr. Sheehan at davidVsheehan@gmail.com.

Requests to access existing non-English translations or for any new translations should be submitted through MAPI Research Trust’s ePROVIDE COA platform at

https://eprovide.mapi-trust.org/ using the following process:

1. Go to Submit a request
2. If you haven't registered yet, you'll be asked to sign up for free
3. Complete the request form. Please attach a copy of the signed and fully executed license agreement signed by Dr. David V Sheehan.

A fully executed license is required for use of the Sheehan-Suicidality Tracking Scale (S-STS) in any language. To license the S-STS directly from Dr. Sheehan, the author and copyright holder, you will need complete his license agreement. Click here to learn more about the S-STS or to download a License for use.

Dr. Sheehan only provides consultation, guidance on regulatory agency questions, and training to those who license the S-STS directly from him. Contact Dr. Sheehan at davidVsheehan@gmail.com for additional information. If you do not see a QR code on the S-STS you are using linking back to this website then you did not get the SDS from the author and Copyright Holder.  Dr. David V. Sheehan is the Copyright Holder, Trademark Holder, and author of the S-STS in all languages.  This copyright for the S-STS has been registered with the US Copyright Office.

The cost of licensing the S-STS is $4 USD for each use, i.e. each administration to a subject and/or each use in training.

Note: Non-profit institutions sometimes incorrectly assume that the license fee does not apply because they are “not-for-profit”. The licensing fee applies to all uses.

The license and license fee applies to all uses.

Dr. Sheehan licenses the S-STS in paper format for distribution as follows: (1) in paper form for any uses, or (2) in fixed-pdf form, paper form, or both for use in clinical or academic research trials or studies.

The S-STS can be used as a systematic means:

• To assess and monitor suicidality in primary care as well as mental health settings (inpatient and outpatient).
• To identify and track suicidality as an efficacy outcome measure, adverse event, and/or treatment emergent effect in clinical trials and treatment outcome studies.
• To provide detailed documentation of suicidality in forensic evaluations.
• To detect and describe the incidence or prevalence and severity of suicidality in population research including national and international epidemiology studies and community surveys.

The S-STS is unique in the following ways:

• The S-STS asks about a broader range of suicidality phenomena than other suicidality scales. For example, beyond suicidal ideation and behavior, it has questions about suicidal impulses, suicidal hallucinations, delusional suicidality, and suicidal dreams.
• Unlike its most used alternative, the C-SSRS, which uses a binary (Yes/No) response format, confirming the presence or absence of suicidality, the S-STS uses a numeric Likert format. A benefit of this format is that it allows raters to make fine distinctions in the seriousness of suicidality symptoms and track changes over time. Also, item and cluster scores can be graphed quantitatively.
• The S-STS can be mapped closely to FDA classification categories of suicidality.
• In clinical trials the S-STS has been found to be uniquely sensitive in detecting drug-placebo differences and treatment effects.
• To our knowledge, the S-STS is the only suicidal assessment scale that has been linguistically validated for children and adolescents.

This is to ensure that the S-STS is administered and interpreted correctly and to reduce the risk of false positives or false negatives. We leave the final decision of selection and credentialing of raters up to the local sites.

Note: Dr. Sheehan only provides consultation, guidance on regulatory agency questions, and training to those who license the Sheehan-Suicidality Tracking Scale (S-STS) directly from him. Contact Dr. Sheehan at davidVsheehan@gmail.com for additional information.  If you do not see a QR code on the Sheehan-Suicidality Tracking Scale (S-STS) you are using linking back to this website, then you did not get the Sheehan-Suicidality Tracking Scale (S-STS) from the author and Copyright Holder.  Dr. David V. Sheehan is the Copyright Holder, Trademark Holder and author of the Sheehan-Suicidality Tracking Scale (S-STS) in all languages.  This copyright for the S-STS has been registered with the US Copyright Office.

Yes. Dr. Sheehan’s license allows you to administer the S-STS remotely as long as you complete the S-STS on paper as a primary source document. It is up to your protocol to determine how appropriate remote administration is for your patient population. Be sure to review HIPAA and GDPR privacy rules. If you are doing research, you should also review other applicable rules to make sure that remote administration is acceptable to any agency, such as the FDA, who may have oversight of your research.

The standard version of the S-STS for adults meets most needs, most of the time in clinical and research settings.

For children and adolescents, the S-STS is available in 3 age-related, linguistically validated versions (for 6 to 8 year olds, 9 to 10 year olds, and 13 to 17 year olds). The pediatric version (S-STS-P) is useful for all three age groups since it can be parent or clinician rated. We recommend the adolescent version (S-STS-A) for adolescents aged 13-17 since it can be either self-rated by the adolescent or clinician rated.

The average time to administer the S-STS is 8.4 minutes. This administration time is comparable to that for the C-SSRS (8.1 minutes) and shorter than that that for the ISST-Plus (14.5 min).

The S-STS can be patient or clinician rated but should always be clinician reviewed, preferably by someone with clinical mental health experience and training. To ensure that the S-STS is rated and interpreted correctly and to reduce the risk of false positives or false negatives, we recommend training in the use of the S-STS. For more information about training, CLICK HERE.

Yes. Please CLICK HERE for a watermarked preview copy for review only or contact Dr. Sheehan at davidVsheehan@gmail.com.

Requests to access existing non-English translations or for any new translations should be submitted through MAPI Research Trust’s ePROVIDE COA platform at

https://eprovide.mapi-trust.org/ using the following process:

1. Go to Submit a request
2. If you haven't registered yet, you'll be asked to sign up for free
3. Complete the request form. Please attach a copy of the signed and fully executed license agreement signed by Dr. David V Sheehan.